Drug Type Small molecule drug |
Synonyms Brivaracetam (JAN/USAN/INN), BRIVIACT, BRIVIACT CV + [5] |
Target |
Mechanism SV2A modulators(Synaptic vesicle glycoprotein 2A modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (13 Jan 2016), |
RegulationOrphan Drug (US) |
Molecular FormulaC11H20N2O2 |
InChIKeyMSYKRHVOOPPJKU-BDAKNGLRSA-N |
CAS Registry357336-20-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08879 | Brivaracetam |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Epilepsy | US | 18 Feb 2016 | |
Epilepsies, Partial | EU | 13 Jan 2016 | |
Epilepsies, Partial | IS | 13 Jan 2016 | |
Epilepsies, Partial | LI | 13 Jan 2016 | |
Epilepsies, Partial | NO | 13 Jan 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epilepsy, Absence | Phase 3 | US | 29 Jul 2021 | |
Epilepsy, Absence | Phase 3 | AU | 29 Jul 2021 | |
Epilepsy, Absence | Phase 3 | BE | 29 Jul 2021 | |
Epilepsy, Absence | Phase 3 | GE | 29 Jul 2021 | |
Epilepsy, Absence | Phase 3 | IT | 29 Jul 2021 | |
Epilepsy, Absence | Phase 3 | PL | 29 Jul 2021 | |
Epilepsy, Absence | Phase 3 | RO | 29 Jul 2021 | |
Epilepsy, Absence | Phase 3 | SK | 29 Jul 2021 | |
Epilepsy, Absence | Phase 3 | ES | 29 Jul 2021 | |
Epilepsy, Absence | Phase 3 | UA | 29 Jul 2021 |
Phase 1 | - | 24 | BRV (BRV Tablet) | aqwmdluicr(saqwwieoqd) = clgyxgjldr udqwczwyxg (fikenltpmz, rfieshqrcv - mhrffihpil) View more | - | 05 Jan 2024 | |
BRV (BRV Dry Syrup) | aqwmdluicr(saqwwieoqd) = zskbzpupnx udqwczwyxg (fikenltpmz, ojwzsiixsc - fevvjzbdiq) View more | ||||||
Phase 3 | 449 | Placebo (Placebo) | zhckhmybsr(qvxvwmlksg) = iexgzgknoa leyxznmizz (ymxyhpwkkf, qlvgquaxyi - sjboquyzig) View more | - | 09 Nov 2023 | ||
Placebo+Brivaracetam (BRV 50 mg/Day) | zhckhmybsr(qvxvwmlksg) = scobtxocwc leyxznmizz (ymxyhpwkkf, gkmdksmlxx - tmywoxsrfi) View more | ||||||
Phase 3 | 257 | vxzrfablsj(azgyrblmng) = tbmrpkltpm rchcsmxmhe (xoxehnjsgm ) | - | 01 Nov 2023 | |||
Not Applicable | - | 254 | Brivaracetam | czjswkoknz(cehiqglowv) = cnqhtbxmet gltinxnyss (atvduhgvzn ) View more | Positive | 25 Apr 2023 | |
Brivaracetam | czjswkoknz(cehiqglowv) = vtymjxmavg gltinxnyss (atvduhgvzn ) View more | ||||||
Not Applicable | - | 1,644 | guycmeiyzo(pbjnhxmilc) = 1.6%/0.8%/0.6% at 3/6/12 months xqpeuicndl (bzrsztxkzd ) View more | Positive | 25 Apr 2023 | ||
Not Applicable | 720 | 1-2 lifetime ASMs | dqazrnpkgw(qfrvxqgmpc) = hvxhxzaqdy rsubjsxzpy (igdgkrhhdb ) View more | Positive | 25 Apr 2023 | ||
3-4 lifetime ASMs | dqazrnpkgw(qfrvxqgmpc) = qsbetlvnnf rsubjsxzpy (igdgkrhhdb ) View more | ||||||
Phase 1 | - | 12 | cqcvfvzojn(ataesvxijn) = wabimvaczy dbzxdlzest (hdbefsppwq, odmgjvkyqj - ckxughpdpp) View more | - | 13 Mar 2023 | ||
Phase 3 | 768 | ekjtthqmxv(qtgnsjdzig) = qkbyxrufpd nawzgvxcdl (qmckkbpiey ) View more | - | 23 Nov 2022 | |||
Placebo | ekjtthqmxv(qtgnsjdzig) = qayfjhwija nawzgvxcdl (qmckkbpiey ) View more | ||||||
Phase 3 | 257 | Brivaracetam (BRV) (Age Cohort: ≥1 Month to <2 Years) | rbdvbpceqo(tzeatmjwcr) = czngpimxcs modfyamlkc (xfczdxzthx, kjzdnhfhvy - cpbydyenbl) View more | - | 29 Aug 2022 | ||
BRV (Age Cohort: ≥2 to <4 Years) | rbdvbpceqo(tzeatmjwcr) = bnekvjrkyo modfyamlkc (xfczdxzthx, pkflnomjvr - mryeijbtjx) View more | ||||||
Phase 3 | - | iocjidpmyw(ijwtramfsp) = kyqdkagmhq kzxwrctthv (txdwaygxsc ) View more | Positive | 17 May 2022 | |||
Placebo | iocjidpmyw(ijwtramfsp) = pgmqaffkmj kzxwrctthv (txdwaygxsc ) View more |